Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?

ITI remains a mainstay for haemophilia treatment of patients with HA with inhibitors, but emicizumab has become a preferred first-line approach to protect against bleeds and represents an alternative to burdensome ITI in certain patient groups.